Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GLS | O94925 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439686 | 0.89 | MEN1 (0.60) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5439630 | 0.87 | MEN1 (0.64) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5443077 | 0.83 | HPN (0.64) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5441175 | 0.82 | KMT2A (0.61) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5439656 | 0.81 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5450985 | 0.80 | KMT2A (0.72) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5446284 | 0.80 | MEN1 (0.59) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5438412 | 0.80 | KMT2A (1.00) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5448515 | 0.79 | MEN1 (0.59) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5439613 | 0.79 | KMT2A (0.62) | KMT2AMEN1NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | claimed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | RAF1, ARAF, JAK1 | KMT2A 1865/4885MEN1 1756/4885NPC1 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.